RE:Why would it ever start trading again?Issues relating to suspension have been addressed since early Nov. TSX says it is slow to process it due to Covid slow downs.
Kalytera Therapeutics applies to have CTO removed
Kalytera Therapeutics Inc (C:KLY)
Shares Issued 546,075,967
Last Close 6/22/2020 $0.025
Tuesday November 10 2020 - News Release
Mr. Robert Farrell reports
KALYTERA ANNOUNCES MAKING REVOCATION APPLICATION TO REMOVE ITS FFCTO AND MAKING REINSTATEMENT APPLICATION TO RESUME TRADING OF ITS SECURITIES
On Nov. 4, 2020, Kalytera Therapeutics Inc. applied to the British Columbia Securities Commission and the Ontario Securities Commission for a full revocation of the failure-to-file cease trade order against the company issued in June 22, 2020, by the BCSC and the OSC.
The FFCTO was due to the company's failure to file by the prescribed filing deadlines its annual financial statements for the year ending December 31, 2019, and the accompanying management's discussion and analysis and certifications. As a result, the TSXV also suspended trading of the company's common shares. The company's auditor, BDO, has completed the audit of the company's financial statements for the year ended December 31, 2019, and the company has filed the audited financial statements for 2019, the quarterly financial statements for Q1 2020 (for period ending in March 31, 2020) and Q2 2020 (for period ending in June 30, 2020), and the accompanying Management's Discussion and Analysis and certifications for all three periods, all of which are available on the company's profile on SEDAR (accessible at www.sedar.com) (the "Filings"). As a result, the company applied to the BCSC and the OSC on November 4, 2020 to have the FFCTO fully revoked, and has applied to the TSXV to have the company's shares resume trading after the FFCTO has been fully revoked.
It is customary to announce such applications after the grant of the removal order, however, due to the level of shareholder inquiry on the status of the company's FFCTO, and with the permission of the BCSC, the company is making this press release. The company is awaiting completion of the application review process of the BCSC, OSC, and TSXV, and appreciates and thanks its shareholders and interested parties for their patience until the process is completed after which the company will make an announcement of the status of the FFCTO, and the resumption of trading of the company's securities.
About Kalytera Therapeutics
Kalytera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs.